S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:ABMD

Abiomed (ABMD) Stock Forecast, Price & News

$235.75
-2.90 (-1.22%)
(As of 05/20/2022 06:55 PM ET)
Add
Compare
Today's Range
$226.46
$242.43
50-Day Range
$233.49
$338.64
52-Week Range
$226.46
$379.30
Volume
515,300 shs
Average Volume
363,665 shs
Market Capitalization
$10.73 billion
P/E Ratio
79.65
Dividend Yield
N/A
Beta
1.34
30 days | 90 days | 365 days | Advanced Chart
Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Abiomed and its competitors with MarketBeat's FREE daily newsletter.

Abiomed logo

About Abiomed

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:ABMD
CUSIP
00365410
Employees
1,725
Year Founded
1981

Sales & Book Value

Annual Sales
$1.03 billion
Cash Flow
$5.45 per share
Book Value
$33.03 per share

Profitability

Net Income
$136.51 million
Pretax Margin
18.47%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,151,000
Market Cap
$10.73 billion
Optionable
Optionable

Company Calendar

Last Earnings
4/28/2022
Today
5/23/2022
Next Earnings (Estimated)
8/03/2022
Fiscal Year End
3/31/2023

Social Links


MarketRank

Overall MarketRank

2.38 out of 5 stars

Medical Sector

208th out of 1,416 stocks

Surgical & Medical Instruments Industry

25th out of 138 stocks

Analyst Opinion: 3.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













Abiomed (NASDAQ:ABMD) Frequently Asked Questions

Is Abiomed a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed
or view top-rated stocks.

When is Abiomed's next earnings date?

Abiomed is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Abiomed
.

How were Abiomed's earnings last quarter?

Abiomed, Inc. (NASDAQ:ABMD) issued its earnings results on Thursday, April, 28th. The medical equipment provider reported $1.16 EPS for the quarter, beating the consensus estimate of $1.08 by $0.08. The medical equipment provider earned $269.50 million during the quarter, compared to analysts' expectations of $267.67 million. Abiomed had a net margin of 13.23% and a trailing twelve-month return on equity of 14.47%. The firm's revenue for the quarter was up 11.7% on a year-over-year basis. During the same period in the previous year, the business posted $1.24 EPS.
View Abiomed's earnings history
.

What guidance has Abiomed issued on next quarter's earnings?

Abiomed updated its FY 2023 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.14 billion-$1.18 billion, compared to the consensus revenue estimate of $1.17 billion.

What price target have analysts set for ABMD?

4 brokerages have issued 1 year price objectives for Abiomed's shares. Their forecasts range from $275.00 to $410.00. On average, they expect Abiomed's share price to reach $335.00 in the next year. This suggests a possible upside of 42.1% from the stock's current price.
View analysts' price targets for Abiomed
or view top-rated stocks among Wall Street analysts.

Who are Abiomed's key executives?
Abiomed's management team includes the following people:
  • Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 55, Pay $2.57M) (LinkedIn Profile)
  • Mr. Todd A. Trapp, CFO & VP (Age 51, Pay $766.73k) (LinkedIn Profile)
  • Mr. Marc A. Began, VP, Gen. Counsel & Sec. (Age 55, Pay $677.86k)
  • Mr. Andrew J. Greenfield, VP & Chief Commercial Officer (Age 49, Pay $638.67k) (LinkedIn Profile)
  • Dr. David M. Weber Ph.D., Scientific & Technology Advisor (Age 61, Pay $754.48k)
  • Dr. Thorsten Siess Ph.D., VP & CTO
  • Ms. Ingrid Goldberg Ward, Director of Investor Relations
  • Sarah Karr, Communications Mang.
  • Mr. Michael G. Howley, VP & GM of Global Sales (Age 58)
  • Ms. Karen Mahoney, Head of Global HR
What is Michael R. Minogue's approval rating as Abiomed's CEO?

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

What other stocks do shareholders of Abiomed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and Salesforce (CRM).

What is Abiomed's stock symbol?

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Who are Abiomed's major shareholders?

Abiomed's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.79%), BlackRock Inc. (10.03%), Baillie Gifford & Co. (8.15%), State Street Corp (4.43%), Wellington Management Group LLP (4.20%) and Primecap Management Co. CA (3.54%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Michael R Minogue, Paul Thomas and Todd A Trapp.
View institutional ownership trends for Abiomed
.

Which institutional investors are selling Abiomed stock?

ABMD stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Baillie Gifford & Co., Gilder Gagnon Howe & Co. LLC, William Blair Investment Management LLC, JPMorgan Chase & Co., Tobam, Primecap Management Co. CA, and Canada Pension Plan Investment Board. Company insiders that have sold Abiomed company stock in the last year include David M Weber, Magdalena Yesil, Martin P Sutter, Michael R Minogue, Paul Thomas, and Todd A Trapp.
View insider buying and selling activity for Abiomed
or view top insider-selling stocks.

Which institutional investors are buying Abiomed stock?

ABMD stock was purchased by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Peregrine Capital Management LLC, New York State Common Retirement Fund, Sei Investments Co., Vanguard Group Inc., Envestnet Asset Management Inc., Ownership Capital B.V., and Swiss National Bank.
View insider buying and selling activity for Abiomed
or or view top insider-buying stocks.

How do I buy shares of Abiomed?

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Abiomed's stock price today?

One share of ABMD stock can currently be purchased for approximately $235.75.

How much money does Abiomed make?

Abiomed has a market capitalization of $10.73 billion and generates $1.03 billion in revenue each year. The medical equipment provider earns $136.51 million in net income (profit) each year or $2.96 on an earnings per share basis.

How many employees does Abiomed have?

Abiomed employs 1,725 workers across the globe.

Does Abiomed have any subsidiaries?

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

When was Abiomed founded?

Abiomed was founded in 1981.

What is Abiomed's official website?

The official website for Abiomed is www.abiomed.com.

How can I contact Abiomed?

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at (978) 646-1400, via email at [email protected], or via fax at 978-777-8411.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.